New
CJC-1295 with DAC
79,99 €
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Sustained increase in GH and IGF-1 with once-weekly administration.
- Increased lean muscle mass and improved body composition.
- Improved fat metabolism, especially visceral fat.
- Improved sleep quality and recovery.
- Supports bone density during long-term use.
Description
CJC-1295 with DAC
Growth Hormone / Anti-Aging
MECHANISM OF ACTION
A GHRH analog using Drug Affinity Complex (DAC) technology, which enables covalent binding to albumin via a lysine-maleimide reaction. It prolongs the half-life to 7–10 days. It continuously activates pituitary GHRH receptors, resulting in a sustained increase in GH and IGF-1. It produces a “drip” of GH rather than a pulsatile release.
KEY BENEFITS
- Sustained increase in GH and IGF-1 with once-weekly administration.
- Increased lean muscle mass and improved body composition.
- Improved fat metabolism, especially visceral fat.
- Improved sleep quality and recovery.
- Supports bone density during long-term use.
SIDE EFFECTS AND SAFETY
Transient water retention, carpal tunnel syndrome-like symptoms at high doses, and potential desensitization with continued use. Monitoring of IGF-1 is recommended. It is not pulsatile, so it may suppress the natural GH rhythm during prolonged use.
RESEARCH AND CLINICAL NOTES
Phase I/II human trials demonstrated 2–10-fold increases in GH AUC for 14 days following injection. IGF-1 rose to 1.5–3 times the baseline level and remained elevated for more than 2 weeks. Walker et al. (2005), JCEM.
TARGET PROFILE:
Anti-aging protocols, HRT treatments, and body optimization programs with weekly injection schedules.
Additional information
| Weight | ,26 kg |
|---|
Related products
New
AOD-9604
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Targeted fat loss without IGF-1-mediated growth effects.
- No effect on blood glucose or insulin sensitivity.
- Fat reduction is well tolerated in patients with metabolic disorders and diabetes.
- It supports body recomposition when combined with exercise.
- Being investigated for cartilage repair (TGA approval in Australia for OA).
New
BPC 157
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Accelerated healing of tendons, ligaments, muscles, and connective tissue.
- Protection of the gastrointestinal mucosa and support for ulcer healing.
- Neuroprotection and peripheral nerve regeneration.
- Powerful anti-inflammatory action through the suppression of pro-inflammatory cytokines.
- Systemic cytoprotective effects on multiple organ systems.
- Benefits at SNC: Research on depression, PTSD, and addictive behavior.
IGF-1 LR3
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Powerful anabolic effect: muscle hypertrophy and hyperplasia.
- Improved protein synthesis and nitrogen retention.
- Improved glucose utilization and fat oxidation.
- Accelerated injury healing and tissue regeneration.
- Extended half-life that allows for once-daily dosing.
MOTS-c
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- AMPK-mediated metabolic improvements, including glucose and fat utilization.
- Mimetic properties of exercise.
- Anti-inflammatory and anti-aging effects.
- Supports bone metabolism through osteoblastic activity.
- Protection against age-related physical decline.
- Potential for research on T2DM and obesity management.
New
NAD+
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Optimization of cellular energy and efficiency in ATP production.
- Activation of sirtuins for the epigenetic regulation of longevity.
- Repair of DNA damage through PARP activation.
- Improved mitochondrial biogenesis.
- Cognitive clarity and support for neurological function.
- Applications in research on addiction and depression.
New
PT-141
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Improved sexual desire in men and women.
- Improvement of erectile function via the central nervous system.
- Approved by the FDA for HSDD in premenopausal women as Vyleesi.
- Effective in patients who do not respond to PDE5 inhibitors.
- It can be used as needed, 45–90 minutes before the activity.
New
Retatrutide 10 mg
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Body weight reduction of up to 24% in Phase II trials; the most potent in its class.
- Greater reduction in body fat compared to tirzepatide.
- Improved glycemic control through multiple mechanisms.
- Improvement in cardiovascular risk factors.
- Potential for treating NASH and reducing liver fat.
New
Semax
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Cognitive improvement: memory, attention, and processing speed.
- Neuroprotection in stroke, traumatic brain injury, and cerebral ischemia.
- Upregulation of BDNF/NGF for neuroplasticity.
- Anxiolytic and antidepressant properties.
- Immune modulation.
- Excellent safety profile: non-addictive and with minimal side effects.
Natural Supplements and Vitamins
Nutrition and Fitness
Beauty and Personal Care
Joint and Muscle Health
Digestive Health and Detox
Immune System
Women’s and Men’s Health
Natural Energy and Antioxidants
Cardiovascular Health
Obesity & Metabolism
